Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide added to radiotherapy and 6-month androgen deprivation therapy in intermediate and limited high-risk localized prostate cancer
2018-000899-15Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of apalutamide in prostate cancer (PCa) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Disease-free survival. Started Oct 2019; status: terminated.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2018-000899-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000899-15.